STOCK TITAN

Chimerix, Inc. - $CMRX STOCK NEWS

Welcome to our dedicated page for Chimerix news (Ticker: $CMRX), a resource for investors and traders seeking the latest updates and insights on Chimerix stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chimerix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chimerix's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.72%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
69.08%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.41%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
conferences earnings
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.79%
Tags
management
Chimerix, Inc.

Nasdaq:CMRX

CMRX Rankings

CMRX Stock Data

88.73M
74.39M
1.34%
50.01%
1.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
DURHAM

About CMRX

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed